GlassScriptPhysician profile
James C Holler
NPI 1295755478
$2,143.72
in general payments reported to CMS, 2019-2025
26 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $294 · 2021: $113 · 2022: $259 · 2023: $372 · 2024: $306 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.71 | 2021-2025 | |
| Novo Nordisk INC | $321.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $249.93 | 2019-2025 | Arexvy |
| Allergan, INC. | $232.27 | 2019-2020 | |
| Pfizer INC. | $138.92 | 2019-2025 | |
| Stryker Corporation | $138.54 | 2019 | |
| Abbott Laboratories | $112.91 | 2019-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $74.67 | 2020-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $69.64 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.79 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $53.71 | 2019-2023 | Rotateq, Vaxelis, Vaqta |
| Astrazeneca Pharmaceuticals LP | $51.36 | 2023-2024 | Farxiga |
| Amgen INC. | $44.56 | 2020-2025 | Otezla, Repatha, Repatha |
| Irhythm Technologies, INC. | $37.62 | 2023 | Zio Xt Patch |
| Corcept Therapeutics | $31.04 | 2023 | Korlym |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.51 | 2019 | |
| Verona Pharma, INC. | $24.24 | 2025 | Ohtuvayre |
| Nevro Corp. | $23.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.00 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $16.89 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $14.43 | 2019 | |
| Si-Bone, INC. | $14.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.89 | 2019 | |
| Neuronetics, INC. | $10.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Holler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.